Back to Top

IDH

0 comments

Submitted by Annemieke DeMaggio on Tue, 08/25/2020 - 10:00

Enasidenib fails OS endpoint in confirmatory phase 3 study

The phase 3 IDHENTIFY study failed to show OS benefit with enasidenib compared to standard treatment options in IDH2mut, r/r AML (BMS press release)